2. Search Result
Search Result
Results for "

LND

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134832
    Mito-LND
    2 Publications Verification

    Mito-Lonidamine

    		 Oxidative Phosphorylation Mitochondrial Metabolism Reactive Oxygen Species Autophagy Cancer
    Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells .
    Mito-LND
  • HY-145767A
    SN-38-CO-DMEDA TFA

    		Others Others
    SN-38-CO-DMEDA TFA is the intermediate product for synthesizing antibody-conjugated drug LND1035 .
    SN-38-CO-DMEDA TFA
  • HY-45545
    Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH

    		Others Others
    Fmoc-gly-gly-ph-gly-nh-ch2-o-ch2cooh can be used to synthesize the ADC Linker, LND1067 .
    Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH
  • HY-155008
    PROTAC HK2 Degrader-1
    2 Publications Verification

    		 Hexokinase Cancer
    PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research .
    PROTAC HK2 Degrader-1
  • HY-129733
    LND 623

    		Na+/K+ ATPase
    LND 623 is an inotropic aminosteroid with positive inotropic properties. LND 623 inhibits Na +/K + ATPase activity. The LD50 of LND 623 infused i.v. is around 45 mg/kg, a value ten times higher than the LD50 for Ouabain (HY-B1457) .
    LND 623
  • HY-136677
    Lnd 796

    		Others Cardiovascular Disease
    LND 796 is an aminosteroidal derivative with positive inotropic effects similar to those of digitalis. It exhibits electrophysiological, toxic, and inotropic effects in normal and partially potassium-depolarized ventricular muscles. LND 796 requires higher concentrations than digoxin to induce the same toxic symptoms. It exhibits a concentration-dependent positive inotropic effect on guinea pig papillary muscles in normal potassium solution. In partially potassium-depolarized papillary muscles, LND 796 enhances both components of contraction and increases the amplitude of slow action potentials. The mechanism of positive inotropic action of LND 796 involves enhanced calcium entry in calcium channels and inhibition of sodium-potassium ATPase. Due to its expanded positive inotropic range, LND 796 may have potential application in the treatment of congestive heart failure.
    Lnd 796
  • HY-144825
    Chol-CTPP

    		Apoptosis Reactive Oxygen Species Cancer
    Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function .
    Chol-CTPP

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: